

FAST RELIEF YOU CAN FEEL



33% reduction in pain scores

31% reduction in stiffness scores

33% improvement in function scores

14 days to significant relief
(first point studied)

Significant improvement in joint comfort and stiffness, with improved physical functioning

- Clinically-demonstrated efficacy
- Experiential relief as soon as 2 weeks
- Novel value proposition for your customers
- Multiple safety studies
- Patented

When consumers look for answers for joint discomfort, they want rapid relief. Compared to some widely popular joint health ingredients that promise relief at two or three months, new Flexir[®] Joint Health Complex from PLT is fast-acting, showing statistically significant reduction in pain scores by 2 weeks. That means you can feature Flexir in your joint health products for a difference that consumers will experience.

Flexir is a patented, synergistic formulation of three botanicals with known benefits in supporting joint health: *Terminalia chebula*, *Curcuma longa*, and *Boswellia serrata*. Flexir is a global formulation, made from hydroethanolic extracts of these herbs, minimizing regulatory issues in markets around the world.

A novel, synergistic formulation of 3 botanicals

Today's consumers are more conscious of joint health than ever. They're actively looking for new answers. This novel combination of ingredients delivers a new value proposition to your customers.


- *Terminalia chebula*
- *Curcuma longa*
- *Boswellia serrata*



Mechanisms of Action

Studies of Flexir demonstrate support for joint structure and function through multiple mechanisms:

- Enhanced chondrocyte survivability under inflammatory (IL-1 β) conditions (in vitro).
- Improved glycosaminoglycan production by human chondrocytes (in vitro).




Synergistic formula enhances chondrocyte proliferation in response to IL-1 β -induced inflammatory insult.

Clinical Efficacy

In a randomized, double-blind, placebo-controlled clinical trial, 105 men and women took 200 or 400 mg per day of Flexir or a matching placebo for 90 days. Those taking Flexir had statistically significant improvement in Total WOMAC scores compared to placebo.

Continuous improvement in Total WOMAC scores was observed throughout the 90-day trial.

WOMAC subscores for pain, stiffness, and physical functioning were similarly improved in a dose-dependent manner throughout the duration of the trial. Visual Analog Scores (VAS) and Lequesne Functional Index (LFI) showed statistically significant improvement compared to placebo as well.



Safety

All three constituents of this new ingredient have been shown to be safe by multiple acute, sub-chronic, and chronic toxicity studies.

Contact PLT Health Solutions for samples and more information.
+1.973.984.0900 • www.PLTHealth.com